Most of the drug remains unmetabolized. No evidence of CYP-inducing effects. Warned against on grounds of high incidence of severe visual impairment.

(To be edited, initial data ST OCT 04) Fatty acid derivative, soluble in water. Used together with other drugs in therapy resistent epilepsy. Irreversible visual field defects takes place with an incidence of 10-20%, limiting the usefulness of the drug. About 60-80 % is eliminated in unchanged form in urine within 24 hours. Vigabatrin does not induce CYPs. EPI-list: safe South African list: use with care French list: avoid, known to have precipitated an acute attack See Hahn et al. Effects of new antikonvulsant medications on porphyrin synthesis in cultured liver cells…Neurology 1997; 49: 97-106. See also Bylesjo. Lakartidningen 1996.

Uneventful use reported in 1 patient with acute porphyria.